N/A
N=15,212
Checklist to Prevent MRSA Surgical Site Infections
Surgical Site Infection
Bottom Line
View on ClinicalTrials.gov: NCT02216227 ↗Enrolled (actual)
15,212
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Participants With Superficial and Deep/Organ Space MRSA Infections Within 90 Days — 70; 25 participants — p=0.13
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mupirocin (Drug); Chlorhexidine gluconate (Drug); Cefazolin (Drug); Vancomycin (Drug); Nasal Povidone Iodine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Feb 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participants With Superficial and Deep/Organ Space MRSA Infections Within 90 Days |
70; 25 | 0.13 |
| SECONDARY Participants With Superficial and Deep/Organ Space MRSA Infections Within 1 Year |
70; 25 | — |
| SECONDARY Participants Compliant With the Entire Pre-surgical Bundle and Individual Bundle Components |
— | — |
| SECONDARY Length of Postoperative Stay |
— | — |
| SECONDARY All-cause Mortality |
— | — |
| SECONDARY Readmission |
— | — |
| SECONDARY Participants With Mupirocin and Chlorhexidine Resistant MRSA Positive Bacterial Isolates |
— | — |
Summary
The goals of this project are 1) to assess the effectiveness and cost-effectiveness of the checklist to prevent MRSA SSIs among Veterans undergoing TJA or cardiac surgery, and 2) to assess barriers and facilitators to checklist implementation.
Hypotheses:
1. The SSI checklist will be effective at reducing MRSA SSIs among total joint arthroplasty and cardiac surgery patients.
2. Implementation of the checklist will be associated with an overall reduction in SSIs caused by all pathogens.
3. The SSI Checklist will be cost-saving since it will prevent many expensive SSIs.
4. Preoperative MRSA testing will be a modifiable barrier to implementing the SSI checklist.
Eligibility Criteria
Inclusion Criteria
Retrospective Control Group Inclusion Criteria:
- Patients identified in VA databases (e.g. VASQIP) by ICD-9 procedure codes as undergoing total joint arthroplasty or cardiac surgery at the 10 intervention VA Medical Centers during the 5 year preintervention period (2008-2013)
Concurrent Non-equivalent Control Group Inclusion Criteria:
- Patients identified in VA databases (e.g. VASQIP) by ICD-9 procedure codes as undergoing total joint arthroplasty or cardiac surgery at VA Medical Centers not included in the intervention group during the 8 years evaluated (5 years pre-intervention to match with the retrospective control group and 3 years of the intervention.)
Exclusion Criteria
For All Patient Groups:
- Have an ICD-9 diagnosis code consistent with endocarditis
- Have any documented infection before the surgical procedure
- Undergo cardiac transplants or cardiac procedures performed using the percutaneous or thoracotomy approach
- Undergoing hip and knee revisions
- Documented allergies to mupirocin
Data sourced from ClinicalTrials.gov (NCT02216227). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.